andrewkaretas, Author at Allogene

4: Statement of changes in beneficial ownership of securities

Post author:andrewkaretas
Post published:December 22, 2025
Post category:SEC Filings

Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

Post author:andrewkaretas
Post published:December 15, 2025
Post category:Latest News

Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China , Clearing the Path…

4: Statement of changes in beneficial ownership of securities

Post author:andrewkaretas
Post published:November 19, 2025
Post category:SEC Filings

Allogene Therapeutics, Inc.

144: Filed by “insiders” prior intended sale of restricted stock.

Post author:andrewkaretas
Post published:November 17, 2025
Post category:SEC Filings

Allogene Therapeutics, Inc.

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

Post author:andrewkaretas
Post published:November 13, 2025
Post category:SEC Filings

Allogene Therapeutics, Inc.

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

Post author:andrewkaretas
Post published:November 13, 2025
Post category:SEC Filings

Allogene Therapeutics, Inc.

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

Post author:andrewkaretas
Post published:November 12, 2025
Post category:SEC Filings

Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Post author:andrewkaretas
Post published:November 10, 2025
Post category:Latest News

SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…